Sionna Therapeutics (NASDAQ:SION) Coverage Initiated at Guggenheim

Investment analysts at Guggenheim began coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a report released on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $45.00 price target on the stock. Guggenheim’s price objective indicates a potential upside of 212.28% from the stock’s previous close.

Sionna Therapeutics Stock Performance

Shares of SION opened at $14.41 on Tuesday. Sionna Therapeutics has a 1 year low of $13.20 and a 1 year high of $25.19.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.